Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths
worldwide. Although advances are being made towards earlier detection and the …

Experimental preclinical models have been a cornerstone of lung cancer translational
research. Work in these model systems has provided insights into the biology of lung cancer …

Cancer evolution is a process that is still poorly understood because of the lack of versatile
in vivo longitudinal studies. By generating murine non–small cell lung cancer (NSCLC) …

Traditional preclinical studies of cancer therapeutics have relied on the use of established
human cell lines that have been adapted to grow in the laboratory and, therefore, may …

Lung cancer accounts for most cancer-related deaths worldwide and has an overall 5-year
survival rate of~ 15%. Cell lines have played important roles in the study of cancer biology …

Background Preclinical models that can better predict therapeutic activity in clinical trials are
needed in this era of personalized cancer treatment. Herein, we established genomically …

Objective: Patient-derived xenograft (PDX) models have shown great promise in preclinical
and translational applications, but their consistency with primary tumors in phenotypic …

Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths worldwide. Only
a fraction of NSCLC harbor actionable driver mutations and there is an urgent need for …

Lung squamous cell carcinoma (LUSC) represents a major subtype of non-small cell lung
cancer with limited treatment options. Previous studies have elucidated the complex genetic …

Patient-derived xenograft (PDX) models are an effective preclinical in vivo platform for
testing the efficacy of novel drugs and drug combinations for cancer therapeutics. Here we …